$398 Million is the total value of DAFNA Capital Management LLC's 87 reported holdings in Q4 2021. The portfolio turnover from Q3 2021 to Q4 2021 was 26.1% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| XENE | Sell | XENON PHARMACEUTICALS INC | $12,579,000 | +102.5% | 402,667 | -1.0% | 3.16% | +91.9% |
| DXCM | Sell | DEXCOM INC | $9,739,000 | -15.8% | 18,138 | -14.2% | 2.45% | -20.1% |
| KRTX | Sell | KARUNA THERAPEUTICS INC | $9,487,000 | +4.0% | 72,423 | -2.9% | 2.39% | -1.4% |
| BHVN | Sell | BIOHAVEN PHARMACTL HLDG CO L | $8,007,000 | -34.6% | 58,100 | -34.1% | 2.01% | -38.0% |
| NBIX | Sell | NEUROCRINE BIOSCIENCES INC | $7,125,000 | -12.2% | 83,655 | -1.2% | 1.79% | -16.8% |
| CYTK | Sell | CYTOKINETICS INC | $6,112,000 | -2.3% | 134,094 | -23.4% | 1.54% | -7.4% |
| RCUS | Sell | ARCUS BIOSCIENCES INC | $4,743,000 | +10.0% | 117,200 | -5.3% | 1.19% | +4.3% |
| OTIC | Sell | OTONOMY INC | $4,577,000 | +0.2% | 2,200,297 | -7.5% | 1.15% | -5.0% |
| AFMD | Sell | AFFIMED N V | $3,153,000 | -47.1% | 571,282 | -40.8% | 0.79% | -49.9% |
| ITOS | Sell | ITEOS THERAPEUTICS INC | $2,518,000 | +12.3% | 54,090 | -34.9% | 0.63% | +6.4% |
| GLPG | Sell | GALAPAGOS NVspon adr | $2,353,000 | -42.4% | 42,675 | -45.1% | 0.59% | -45.4% |
| VERO | Sell | VENUS CONCEPT INC | $1,659,000 | -40.6% | 975,687 | -12.4% | 0.42% | -43.7% |
| PHAS | Sell | PHASEBIO PHARMACEUTICALS INC | $988,000 | -47.3% | 378,611 | -37.2% | 0.25% | -50.1% |
| HOOK | Sell | HOOKIPA PHARMA INC | $747,000 | -60.6% | 320,444 | -0.5% | 0.19% | -62.6% |
| PRQR | Sell | PROQR THERAPEUTICS N V | $685,000 | -72.4% | 85,476 | -71.2% | 0.17% | -73.9% |
| STRO | Sell | SUTRO BIOPHARMA INC | $670,000 | -58.3% | 45,000 | -47.1% | 0.17% | -60.6% |
| GNFT | Sell | GENFIT S Aads | $302,000 | -56.7% | 60,448 | -67.9% | 0.08% | -58.9% |
| VBLT | Exit | VASCULAR BIOGENICS LTD | $0 | – | -55,000 | -100.0% | -0.03% | – |
| ALPN | Exit | ALPINE IMMUNE SCIENCES INC | $0 | – | -111,501 | -100.0% | -0.32% | – |
| IFRX | Exit | INFLARX NV | $0 | – | -600,000 | -100.0% | -0.41% | – |
| KDMN | Exit | KADMON HLDGS INC | $0 | – | -314,561 | -100.0% | -0.73% | – |
| FSII | Exit | FS DEVELOPMENT CORP II | $0 | – | -299,950 | -100.0% | -0.79% | – |
| DRNA | Exit | DICERNA PHARMACEUTICALS INC | $0 | – | -587,456 | -100.0% | -3.14% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| STEREOTAXIS INC | 42 | Q3 2023 | 27.6% |
| ATRICURE INC | 42 | Q3 2023 | 11.4% |
| MASIMO CORPORATION | 42 | Q3 2023 | 1.8% |
| ASCENDIS PHARMA A S SPONSORED | 34 | Q3 2023 | 4.5% |
| AERIE PHARMACEUTICALS INC | 33 | Q3 2022 | 4.2% |
| GALAPAGOS NV-SPON ADR | 33 | Q3 2023 | 3.8% |
| XENON PHARMACEUTICALS INC | 33 | Q3 2023 | 3.6% |
| NEUROCRINE BIOSCIENCES INC | 32 | Q3 2023 | 2.9% |
| JOHNSON AND JOHNSON | 32 | Q1 2021 | 1.2% |
| ISHARES TR NASDQ BIOTECH | 30 | Q3 2023 | 4.0% |
View DAFNA Capital Management LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Stereotaxis, Inc. | March 08, 2018 | 13,680,554 | 23.4% |
| SUNESIS PHARMACEUTICALS INC | February 14, 2018 | 983,000 | 2.9% |
| SUNESIS PHARMACEUTICALS INC | February 14, 2017 | 1,133,583 | 5.4% |
| WINDTREE THERAPEUTICS INC /DE/ | February 14, 2017 | 208,333 | 2.4% |
| ANAVEX LIFE SCIENCES CORP.Sold out | February 16, 2016 | 0 | 0.0% |
| DISCOVERY LABORATORIES INC /DE/ | February 16, 2016 | 10,658,699 | 9.2% |
| PRECISION OPTICS CORPORATION, INC. | February 13, 2015 | 311,537 | 5.0% |
| TearLab Corp | February 14, 2013 | 939,239 | 3.2% |
| VIKING SYSTEMS INC | February 14, 2012 | 3,781,468 | 5.2% |
View DAFNA Capital Management LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| SC 13G/A | 2023-02-14 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
View DAFNA Capital Management LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.